Show simple item record

dc.contributor.authorStøer, Nathalie Charlotte
dc.contributor.authorVangen, Siri
dc.contributor.authorSingh, Deependra
dc.contributor.authorTurzanski Fortner, Shannon Renee
dc.contributor.authorHofvind, Solveig Sand-Hanssen
dc.contributor.authorUrsin, Giske
dc.contributor.authorBotteri, Edoardo
dc.date.accessioned2024-10-07T09:07:17Z
dc.date.available2024-10-07T09:07:17Z
dc.date.issued2024-04-13
dc.description.abstract<p>BACKGROUND: It is important to monitor the association between menopausal hormone therapy (HT) use and breast cancer (BC) risk with contemporary estimates, and specifically focus on HT types and new drugs. <p><p>METHODS: We estimated hazard ratios (HR) of BC risk according to HT type, administration route and individual drugs, overall and stratified by body mass index (BMI), molecular subtype and detection mode, with non-HT use as reference. <p>RESULTS: We included 1,275,783 women, 45+ years, followed from 2004, for a median of 12.7 years. Oral oestrogen combined with daily progestin was associated with the highest risk of BC (HR 2.42, 95% confidence interval (CI) 2.31–2.54), with drug-specific HRs ranging from Cliovelle®: 1.63 (95% CI 1.35–1.96) to Kliogest®: 2.67 (2.37–3.00). Vaginal oestradiol was not associated with BC risk. HT use was more strongly associated with luminal A cancer (HR 1.97, 95% CI 1.86–2.09) than other molecular subtypes, and more strongly with interval (HR 2.00, 95% CI: 1.83–2.30) than screen-detected (HR 1.33, 95% CI 1.26–1.41) BC in women 50–71 years. HRs for HT use decreased with increasing BMI. <p>CONCLUSIONS: The use of oral and transdermal HT was associated with an increased risk of BC. The associations varied according to HT type, individual drugs, molecular subtype, detection mode and BMI.en_US
dc.identifier.citationStøer, Vangen, Singh, Turzanski Fortner, Hofvind, Ursin, Botteri. Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. British Journal of Cancer. 2024en_US
dc.identifier.cristinIDFRIDAID 2272193
dc.identifier.doi10.1038/s41416-024-02590-1
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.urihttps://hdl.handle.net/10037/35072
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalBritish Journal of Cancer
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 World Health Organization and The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleMenopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norwayen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)